Eloxx Pharmaceuticals grants director 13,587 options

The award vests in monthly installments subject to continued service, with full vesting and exercisability on the last day of the second-anniversary month.

Rhea-AI Filing Summary

Eloxx Pharmaceuticals, Inc. director Geno J. Germano received a direct grant of stock options covering 13,587 common shares on October 19, 2026. The options have a $12.50 exercise price per share and expire October 19, 2036. Subject to continuous service through each vesting date, they vest in 24 substantially equal monthly installments and become fully vested and exercisable on the last day of the month of the second anniversary of the grant date.

Insider Trade Summary

Grant/Award: 13,587 shares

Grant/Award 1 txn

Insider Germano Geno J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	13,587	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 13,587 contracts (Direct)

Footnotes (1)

1. F1. The stock option will vest, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date, in 24 substantially equal monthly installments on the last day of the month so that the option will be fully vested and exercisable on the last day of the month of the second anniversary of the grant date.

Key Figures

Stock options granted: 13,587 options covering common shares Exercise price: $12.50 per share Option expiration: October 19, 2036 +1 more

4 metrics

Stock options granted 13,587 options covering common shares Granted October 19, 2026

Exercise price $12.50 per share For the granted options

Option expiration October 19, 2036 Expiration date

Vesting installments 24 installments Substantially equal monthly installments, subject to continuous service

Key Terms

Stock Option (Right to Buy), vest, exercisable

3 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

vest financial

"will vest, subject to the Reporting Person's continuous service"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercisable financial

"fully vested and exercisable on the last day of the month"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did ELOX director Geno J. Germano receive?

Geno J. Germano received options covering 13,587 common shares on October 19, 2026.

When do Geno J. Germano's ELOX options vest?

The options vest in 24 substantially equal monthly installments, subject to continuous service through each vesting date, and become fully vested and exercisable on the last day of the month of the grant date's second anniversary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/21/2026 - 07:33 PM EDT Accepted by SEC EDGAR 10/21/2026 - 07:33 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Germano Geno J

(Last) (First) (Middle)

C/O ELOXX PHARMACEUTICALS, INC.

P.O. BOX 274

(Street)

ARLINGTON MASSACHUSETTS 02476

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Eloxx Pharmaceuticals, Inc. [ ELOX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.5	10/19/2026		A		13,587		(1)	10/19/2036	Common Stock	13,587	$0	13,587	D

Explanation of Responses:

1. The stock option will vest, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date, in 24 substantially equal monthly installments on the last day of the month so that the option will be fully vested and exercisable on the last day of the month of the second anniversary of the grant date.

	/s/ Sumit Aggarwal, Attorney-in-Fact	10/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)